Molecular and Cellular Biochemistry

, Volume 129, Issue 2, pp 195–200 | Cite as

Inhibition of tumor necrosis factor-alpha by thalidomide in magnesium deficiency

  • William B. Weglicki
  • Richard E. Stafford
  • Benjamin F. Dickens
  • I. Tong Mak
  • Marie M. Cassidy
  • Terry M. Phillips
Article

Abstract

The effect of thalidomide on circulating cytokines and myocardial lesion formation was investigated in Mg-deficient rats. After two weeks on a Mg-deficient diet, rats show an increase in circulating levels of tumor necrosis factor-alpha and interleukin 1. Thalidomide (1 mg/day) caused a complete inhibition of the increase in circulating tumor necrosis factor-alpha levels, without having an effect on interleukin 1. However, a marked increase in cardiomyopathic lesion formation was observed in Mg-deficient animals treated with thalidomide; possible mechanisms for thalidomide's enhancement of myocardial injury are discussed. (Mol Cell Biochem129: 195–200, 1993)

Key words

magnesium-deficiency rats tumor necrosis factor thalidomide interleukin-1 myocardial necrosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Freedman AM, Atrakchi AH, Cassidy MM, Weglicki WB: Magnesium deficiency-induced cardiomyopathy: Protection by vitamin E. Biochem Biophys Res Commun 170:1102–1106, 1990Google Scholar
  2. 2.
    Weglicki WB, Freedman AM, Bloom S, Atrakchi AH, Cassidy MM, Dickens BD, Mak IT: Antioxidants and the cardiomyopathy of Mg-deficiency. Am J Cardiovasc Pathol 4:210–215, 1992Google Scholar
  3. 3.
    Freedman AM, Cassidy MM, Weglicky WB: Magnesium-deficient myocardium demonstrates an increased susceptibility to anin vivo oxidative stress. Magnesium Res 4:185–189, 1991Google Scholar
  4. 4.
    Freedman AM, Cassidy MM, Weglicki WB: Captopril protects against myocardial injury by magnesium deficiency. Hypertension 18:142–147, 1991Google Scholar
  5. 5.
    Atrakchi AH, Bloom S, Dickens BF, Mak IT, Weglicki WB: Hypomagnesemia and isoproterenol cardiomyopathies: Protection by probucol. J Cardiovasc Pathol 1:155–160, 1992Google Scholar
  6. 6.
    Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF: Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem 110:169–173, 1992Google Scholar
  7. 7.
    Weglicki WB, Phillips TM: Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 263:R734-R737, 1992Google Scholar
  8. 8.
    Weglicki WB, Stafford RE, Freedman AM, Cassidy MM, Phillips TM: Modulation of cytokines and myocardial lesions by vitamin E and chloroquine in a Mg-deficient rat model. Am J Physiol 264: 723–726, 1993Google Scholar
  9. 9.
    Sampaio EP, Sarno EN, Galilly R, Chon ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699–703, 1991Google Scholar
  10. 10.
    Griffith OW: Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106:207–210, 1980Google Scholar
  11. 11.
    Mak IT, Boehme P, Weglicki WB: Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 70:1099–1103, 1992Google Scholar
  12. 12.
    Lenz W: A short history of thalidomide embryopathy. Teratology 38:203–215, 1988Google Scholar
  13. 13.
    Vogelsang CB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055–1058, 1992Google Scholar
  14. 14.
    Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Bonnetblanc JM, Claudy A, Dallac S, KLene C: Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 126:923–927, 1990Google Scholar
  15. 15.
    Burrows NP, Walport MJ, Hammond AH, Davey N, Jones RR: Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol 125:62–67, 1991Google Scholar
  16. 16.
    Larsson H: Treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217). J Intern Med 228:405–407, 1990Google Scholar
  17. 17.
    Gutierrez-Rodriquez O, Starusta-Bacal P, Gutierrez-Montes O: Treatment of refractory rheumatoid arthritis — the thalidomide experience. J Rheumatol 16:158–163, 1989Google Scholar
  18. 18.
    Gutierrez-Rodriquez O, Starusta-Bacal P, Gutierrez-Montes O: Thalidomide-induced neuropathy in rheumatoid arthritis patients [letter]. Arthritis Rheum 31(1):145–146, 1988Google Scholar
  19. 19.
    Ostraat O, Ekberg H, Schatz H, Riesbeck K, Eriksson T: Thalidomide prolongs graft survival in rat cardiac transplants. Transplant Proc 24:2624–2625, 1992Google Scholar
  20. 20.
    Tamura FG, Vogelsang B, Reitz BA, Baumgartner WA, Herskowitz A: Comparison with combination methylprednisolone and cyclosporine. Transplantation 49:20–25, 1990Google Scholar
  21. 21.
    Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G: æ Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 175:1729–1737, 1992Google Scholar
  22. 22.
    Sarno EN, Grau GE, Vieira LMM, Nery JA: Serum levels of tumour necrosis factor-alpha and interleukin-1β during leprosy reactional states. Clin Exp Immunol 84:103–108, 1991Google Scholar
  23. 23.
    Arbustini E, Grasso M, Diegoli M, Barerio M, Scotti-Foglieni A, Albertario M, Martinelli L, Gavazzi A, Goggi C, Campand C, Vigano M: Expression of tumor necrosis factor in human acute ear diac rejection — An immunohistochemical and immunoblouing study. Am J Pathol 139:709–751, 1991Google Scholar
  24. 24.
    Freedman AM, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Muesing RA, Weglicki WB: Erythrocytes from magnesium-deficient hamsters display an enhanced susceptibility to oxidative stress. Am J Physiol Cell Physiol 262:C1371-C1375, 1992Google Scholar
  25. 25.
    Murphy HS, Shayman JA, Till GO, Mahroughui M, Owens CB, Ryan US, Ward PA: Superoxide response of endothelia cells to C5a and TNF-alpha: divergent signal transduction pathways. Am J Physiol 263:L51-L59, 1992Google Scholar
  26. 26.
    Bautista AP, Schuler A, Spolarics Z, Spitzer JJ: Tumor necrosis factor-alpha stimulates superoxide anion generation by perfused rat liver and Kupffer cells. Am J Physiol 261:G891-G895, 1991Google Scholar
  27. 27.
    Braquet P, Hosford D, Koltz P, Guildbaud J, Paubert-Braquet M: Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins. Lipids 26:1071–1075, 1991Google Scholar
  28. 28.
    Whicher JT, Evans SW: Cytokines in disease. Clin Chem 36:1269–1281, 1990Google Scholar
  29. 29.
    Brown JM, Anderson BO, Repine JE, Shanley PF, While CW, Grosso MA, Banerjee A, Bensard DD, Harken AH: Neuthophils contribute to TNF induced myocardial tolerance to ischemia. J Mol Cell Cardiol 24:485–495, 1992Google Scholar
  30. 30.
    Günther T, Vormann J, Höllriegl V, Disch G, Classen HG: Role of lipid peroxidation and vitamin E in magnesium deficiency. Mg Bull 14:57–66, 1992Google Scholar
  31. 31.
    Günther T, Höllriegl V, Vormann J, Disch G, Classen HG. Effects of isoproterenol and magnesium deficiency on vitamin E content, lipid peroxidation, and mineral metabolism of various tissues. Mg Bull 14:81–87, 1992Google Scholar
  32. 32.
    Dickens BF, Weglicki WB, Li Y-S, Mak IT: Magnesium deficiencyin vitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells. FEBS Lett 311:187–191, 1992Google Scholar
  33. 33.
    Günther T, Höllriegl V: Increased lipid peroxidation in liver mitochondria from Mg-deficient rats. J Trace Elem Electrolytes Health Dis 3:213–216, 1989Google Scholar
  34. 34.
    Günther T, Vormann J, Höllriegl V, Disch G, Classen HG: Effect of Fe loading on vitamin E and malondialdehyde of liver, heart, and kidney from rats fed diets containing various amounts of magnesium and vitamin E. Mg Bull 14:88–93, 1992Google Scholar
  35. 35.
    Gordon CB, Spielberg SP, Blake DA, Balasubramanian V: Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA 78:2545–2548, 1981Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • William B. Weglicki
    • 1
    • 2
  • Richard E. Stafford
    • 1
  • Benjamin F. Dickens
    • 1
    • 2
  • I. Tong Mak
    • 1
    • 2
  • Marie M. Cassidy
    • 2
  • Terry M. Phillips
    • 1
  1. 1.Department of MedicineGeorge Washington University Medical CenterWashington DCUSA
  2. 2.Department of PhysiologyGeorge Washington University Medical CenterWashington DCUSA

Personalised recommendations